stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Gross margin
Beam Therapeutics Inc.'s gross margin over the twelve months to 30 September 2026 was 100.0%, down 0.0 percentage points from fiscal 2025 (100.0%). Over the past ten years it has ranged from 0.00% (fiscal 2018) to 100.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 100.0% | 0.00 |
| FY2024 | 100.0% | 0.00 |
| FY2023 | 100.0% | 0.00 |
| FY2022 | 100.0% | 0.00 |
| FY2021 | 100.0% | 0.00 |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 100.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 100.0% | 0.00 |
| Jun 2026 | 100.0% | 0.00 |
| Mar 2026 | 100.0% | 0.00 |
| Dec 2025 | 100.0% | 0.00 |
| 26 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| XNCR Xencor, Inc. compare | 100.0% |
| RCUS Arcus Biosciences, Inc. compare | 100.0% |
| BEAM Beam Therapeutics Inc. | 100.0% |
| IDYA IDEAYA Biosciences, Inc. compare | 100.0% |
| VRDN Viridian Therapeutics, Inc. compare | 100.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | 100.0% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | — |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement